Carisma Therapeutics Inc. (CARM) Quality Score
Valuation is the primary weakness (avg 50/100). Business quality is the relative bright spot.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Under 20x, reasonable relative to earnings
Not enough quarterly data
for a 1-year trend
Negative FCF, no valuation support
Above 10% CAGR, strong compounder
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Heavy dilution above 5%
Expanded 3+pp, strong improvement
Net cash position, no leverage concern
Above 20%, exceptional capital efficiency
Carisma Therapeutics (CARM) quality: score, margins and returns
Carisma Therapeutics (CARM) scores 60/100 on Intrinsiqq's quality score (a solid business), a weighted blend of 7 metrics each scored 0 to 100, on 20.6% operating margins and 471.6% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Carisma Therapeutics (CARM) a high-quality business?+
Carisma Therapeutics scores 60 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which rates it a solid business on these measures. Recent figures include a 20.6% operating margin and a 471.6% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Carisma Therapeutics's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from CARM's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Carisma Therapeutics scores well and where it falls behind.
What is Carisma Therapeutics's return on invested capital (ROIC)?+
Carisma Therapeutics earns about 471.6% on its invested capital, which is exceptional. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to CARM's margins and growth on this scorecard to judge durability.
How profitable is Carisma Therapeutics?+
Carisma Therapeutics runs an operating margin of about 20.6% and a net margin of about 15.3%. Revenue has grown at roughly 117.1% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.
SourceQuality score computed from the 10-Q filed 5 Nov 2025, covering the period ending 30 Sept 2025, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.